Full Press Release Details
Inc. Announces Filing of Delayed 10-Q Quarterly Report
BROOMFIELD, CO, August 25, 2023 - Aclarion, Inc.,
("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers
and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that
it was not able to file its Quarterly Report for the quarter ended June 30, 2023 by the August 21, 2023 extended filing deadline established
by the Securities and Exchange Commission. The Company, therefore, is a late filer with respect to such report.
The delay in the filing of the Company's Quarterly
Report relates principally to completion of the review process by the Company's new independent accountant, CohnReznick LLP.
The Company filed the Quarterly Report on August 25,
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages
Magnetic Resonance Spectroscopy ("MRS"), proprietary signal processing techniques, biomarkers, and augmented intelligence
algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first,
evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine.
Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being
evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated
with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other
diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity
to optimize treatment strategies. For more information, please visit www.aclarion.com - Opens in new window.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934 about the Company's current expectations about future results, performance, prospects and opportunities.
Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions,
are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are
subject to a number of uncertainties and risks that could significantly affect the Company's current plans and expectations, as well as
future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings
with the Securities and Exchange Commission. Readers are encouraged to review the section titled "Risk Factors" in the Company's
Annual Report on Form 10-K for the year ended December 31, 2022, as well as other disclosures contained in subsequent filings made with
the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company
undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events